Evidence map›Paper›PMID 40072436›Full record

ArticleJAMA network open2025

Estimated Cancer Risk in Females Who Meet the Criteria to Exit Cervical Cancer Screening.

Shalini L Kulasingam, Inge M C M de Kok, Abhinav Mehta, Erik E L Jansen, Mary Caroline Regan, James W Killen, Stephen Sy, Ran Zhao, Karen Canfell, Jane J Kim and 2 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shalini L KulasingamDivision of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis.
Inge M C M de KokErasmus University Medical Center, Rotterdam, the Netherlands.
Abhinav MehtaDivision of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis.
Erik E L JansenErasmus University Medical Center, Rotterdam, the Netherlands.
Mary Caroline ReganCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
James W KillenThe Daffodil Centre, University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, Australia.
Stephen SyCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Ran ZhaoDivision of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis.
Karen CanfellThe Daffodil Centre, University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, Australia.
Jane J KimCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Megan A SmithThe Daffodil Centre, University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, Australia.
Nicole G CamposCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Funding

Comparative Modeling to Inform Cervical Cancer Control Policies: USPSTF SupplementU01CA253912 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI BARNABAS, RUANNE VANESSA, CANFELL, KAREN · 2020 to 2024
$7.9M
Comparative Modeling to Inform Cervical Cancer Control PoliciesU01CA199334 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI BARNABAS, RUANNE VANESSA, CANFELL, KAREN · 2015 to 2019
$6.4M
NCI NIH HHS U01 CA199334NCI NIH HHS U01 CA253912
6 · The paper itself

Abstract

Importance: Cervical screening guidelines in the US recommend that most females can exit routine screening at age 65 years following 2 recent consecutive negative cotest results (concurrent human papillomavirus and cytology tests). However, empirical data on the subsequent risks of cancer and cancer death in this subgroup of females are limited. Objective: To estimate the risks of cervical cancer and cervical cancer death among females who meet the cotesting criteria to exit screening. Design, Setting, and Participants: In this decision analytical comparative modeling study, 4 decision analytical models from the Cancer Intervention and Surveillance Modeling Network-Cervical modeling consortium that fit common US epidemiological data targets were validated against published estimates of 3- and 5-year risks of cervical intraepithelial neoplasia grade 3 (CIN3) among females meeting exit criteria at Kaiser Permanente Northern California (KPNC). Main Outcomes and Measures: Age-conditional and cumulative risks of cervical cancer and cervical cancer death at ages 65, 70, 75, 80, and 85 years were estimated by performing a comparative modeling analysis of the 4 models to estimate the risks of cervical cancer and cervical cancer death after exiting screening. Results: All models estimated a 5-year risk of CIN3 that was within the range of empirical data from KPNC. Projections of the cumulative and age-conditional risks of cervical cancer and cervical cancer death increased with time since exiting screening. The cumulative risks of cervical cancer and cervical cancer death by age 70 years were estimated to range from 0.001% to 0.003% and from 0% to 0.001%, respectively. The cumulative risks of cervical cancer and cervical cancer death by age 85 years ranged from 0.026% to 0.081% and from 0.005% to 0.038%, respectively, across models. Results were sensitive to assumptions about screening test sensitivity and incidence of high-risk human papillomavirus. Conclusions and Relevance: In this decision analytical comparative modeling study, a low risk of cervical cancer and cervical cancer death was estimated among females who fulfilled the US criteria to exit screening with cotesting; however, the risks increased with age and/or time since screening exit. The findings suggest that future guidelines should consider acceptable risk levels when defining screening modality and exit age requirements.

Indexed as

Early Detection of CancerMass ScreeningUterine Cervical DysplasiaUterine Cervical NeoplasmsAgedAged, 80 and overCaliforniaFemaleHumansPapillomavirus InfectionsRisk Assessment

Identifiers

PMID40072436
PMCPMC11904717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.